1. Home
  2. EPOW vs ITRM Comparison

EPOW vs ITRM Comparison

Compare EPOW & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EPOW

Sunrise New Energy Co. Ltd

HOLD

Current Price

$0.75

Market Cap

29.5M

ML Signal

HOLD

Logo Iterum Therapeutics plc

ITRM

Iterum Therapeutics plc

HOLD

Current Price

$0.16

Market Cap

24.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EPOW
ITRM
Founded
2014
2015
Country
China
Ireland
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.5M
24.3M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
EPOW
ITRM
Price
$0.75
$0.16
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.00
AVG Volume (30 Days)
158.6K
1.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$947.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.66
$0.14
52 Week High
$1.86
$1.49

Technical Indicators

Market Signals
Indicator
EPOW
ITRM
Relative Strength Index (RSI) 41.53 34.51
Support Level $0.66 N/A
Resistance Level $1.02 $0.39
Average True Range (ATR) 0.06 0.03
MACD 0.00 -0.01
Stochastic Oscillator 0.00 15.46

Price Performance

Historical Comparison
EPOW
ITRM

About EPOW Sunrise New Energy Co. Ltd

E Power Inc, through its subsidiaries, is engaged in the manufacturing and sale of graphite anode material for lithium-ion batteries. The company operates a plant in Guizhou Province, China, powered by electricity from renewable sources, which contributes to the plant's low production costs and reduced environmental impact in the production of graphite anode materials. Additionally, it also operates a knowledge sharing platform business.

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Share on Social Networks: